

August 04, 2026

To
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Symbol: SAMBHV

To
Listing Compliance Department
BSE Limited
P J Towers, Dalal Street,
Mumbai - 400 001
Scrip Code: 544430

Dear Sir / Madam

Sub: Submission of copies of Newspaper publication of Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.

Pursuant to Regulation 30 read with Para A of Part A of Schedule III and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the copies of the Financial Results for the quarter ended June 30, 2026 published in Business Line (English) and Amrit Sandesh (Hindi) Newspapers on August 04, 2026.

This is for your information and records.

Thanking you,

For, Sambhv Steel Tubes Limited

Niraj Shrivastava
(Company Secretary and Compliance Officer)
Membership No. F8459

QUICKLY.

KKR to Buy Integer Holdings for \$4.3 billion



Bengaluru: Private equity giant KKR will take Integer Holdings private in an all-cash deal valued at about \$5.7 billion, the medical-device outsourcing firm said on Monday. KKR's takeover of Integer comes amid continued private equity interest in healthcare, with buyout firms deploying significant reserves of untapped capital to pursue acquisitions and expand their portfolios. The deal with KKR is expected to close by the end of the year, Integer Holdings said. *sources*

Visa to buy cyberspace player BioCatch for \$2.4 billion

Bengaluru: Visa said it would buy fraud intelligence provider BioCatch for \$2.4 billion in cash from investment firm Permira and other investors, marking the card giant's latest effort to beef up its cybersecurity offerings. The deal would help the world's largest payment processor further bolster its existing cyber, fraud, risk and security offerings and enable it to help clients better protect themselves in an increasingly complex threat environment, Visa said. The BioCatch deal is expected to close by the end of Visa's fiscal second quarter of 2027. *Reuters*

FSSAI pulls up alcobev players over non-permitted flavours

RIGHT LABELLING. Not tagging products as 'flavoured/premium rum' may be misleading

Our Bureau
New Delhi

The Food Safety and Standards Authority of India (FSSAI) has taken action against leading alcobev players for adding non-permitted flavours in products such as rum and whiskey that mimic their chemical composition, in violation of regulations. The action includes prohibition of sale order against products made in some manufacturing units, notices and inspection in certain States.

The regulator said that it has barred the sale of McDowell's No 1 Rum, Antiquity Blue Whiskey, Royal Challenge Whisky made by Diageo's United Spirits in Baramati and Madhya Pradesh. Similarly, prohibition of sale orders were issued again Khopoli unit of Mohan Rocky Springwater for three Old Monk Rum variants, which include the Legend, Gold Reserve, XXX Matured Rum, INBREW Beverages, Madhya Pradesh for Bee, Piper Deluxe Whisky and Old Cask deluxe XXX Rum, Associated Alcohols & Breweries, Madhya Pradesh for brands, Central Province Whisky, McDowell's No 1 Celebration matured XXX Rum. Notices have also been issued to six other manufacturers in the State of Maharashtra in this case and further necessary action to follow soon, the food safety regulator stated



QUALITY IMPACTED. It also said that lab reports, post the testing of samples of these products, stated that "the addition of artificial flavours is masking its natural flavour and making the product substandard"

on Sunday. The action is State-specific because alcohol samples were tested from different States. FSSAI said manufacturers cannot add additives to mislead consumers and that its standards are instituted to ensure that the chemical composition of such beverages remains authentic to their raw material origins. It had first issued notices to alcobev players on this matter last month consequently some players are looking at legal recourse on this matter.

MIMIC NOT REAL

Clarifying its position on this matter, the food safety regulator said that it found that some alcobev manufacturers are externally adding flavour, which mimic the product's inherent aroma and taste but are sold as a standard products, which misleads consumers. "The potential

need for the addition of such flavour is observed due to an existing malpractice wherein manufacturers, instead of creating products through maturation and/or from base materials such as molasses, malt, or grapes to develop their flavour naturally, use spirit/neutral alcohol primarily, which has no specific flavour and therefore add flavour externally," it added.

The regulator said that such products are not "only sub-standard" but are also "misrepresented" as they are labelled under standard categories.

"At best, they can be identified as rum-flavoured spirit or whiskey-flavoured spirit, etc. Further, the front-of-the-pack completely fails to disclose the true nature of the product," it added.

It also said that lab reports post testing of samples

of these products stated that "the addition of artificial flavours is making its natural flavour and making the product substandard." Also failing to name these products as "flavoured or premium rum" on the product label may mislead or be deceptive to the consumers, FSSAI's statement added.

FSSAI stressed that the use of natural and nature-identical flavouring substances is permissible under the applicable regulations governing alcoholic beverages. "The present matter, however, does not pertain to a prohibition on the use of flavouring substances.

Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth.

Cancer treatments accounted for about \$25 billion in 2025 sales, nearly half of

AstraZeneca holds talks with Bristol Myers Squibb on \$400 billion deal

Reuters

UK drugmaker AstraZeneca has been exploring a deal to combine with US rival Bristol Myers Squibb, the *Financial Times* reported on Sunday, citing people familiar with the matter.

The deal could create one of the world's biggest pharmaceutical companies with a combined value of nearly \$400 billion.

The companies have held talks on a potential tie-up in recent months, the report said, adding that a deal could materialise soon, but could also be delayed or fall apart.

Reuters could not immediately verify the report. AstraZeneca declined to comment, while Bristol Myers did not immediately respond to a Reuters request for comment.

Last year, AstraZeneca unveiled plans for a direct US listing, aiming to capitalise on stronger valuations in the US market while remaining listed in London.

STRONG GROWTH

AstraZeneca's share price has more than quadrupled during Pascal Soriot's 14-year tenure as CEO, soaring above the wider FTSE 100 index and main British rival GSK.

Second-quarter results last week showed strong demand for cancer and rare disease drugs continues to drive growth.

Cancer treatments accounted for about \$25 billion in 2025 sales, nearly half of



GIANTS UNITE. Both companies have significant cancer drug portfolios, and a merger would be the biggest global pharma deal since 2020

the total, followed by cardiovascular, renal and metabolic treatments worth about \$12 billion.

Combining with Bristol Myers, whose shares are up around 44 per cent over the last year, could draw attention from antitrust regulators. Oncology drugs accounted for over 40 per cent of its overall sales in the first six months of 2026, and the two companies' cancer immunotherapies directly compete.

"I would expect a Trump FTC to scrutinise the merger and if there are significant overlaps in certain drugs and late stage pipeline overlaps it would require meaningful divestitures," said antitrust lawyer Andre Barlow with DBM Law Group, referring to the US Federal Trade Commission.

Bristol Myers has been doing smaller deals to gain new drugs as it faces declining sales of older medicines,

some of which will soon face generic competition.

In 2019, Bristol Myers bought Celgene for about \$80 billion, acquiring its flagship blood cancer drug Revlimid, which became Bristol's top-selling product. Revlimid has already lost patent protection and its current top sellers — cancer immunotherapy Opdivo and blood thinner Eliquis — could lose patent protection by 2028.

The report of the potential deal comes about a dozen years after AstraZeneca fended off a takeover attempt by larger US rival Pfizer.

Large pharma deals have been rare in recent years, in part due to concerns about antitrust and US pressure to keep drug prices low. Besides Bristol and Celgene, AbbVie bought Allergan in 2020 and Takeda and Shire combined in 2019.

Honda emerges as largest 2-wheeler OEM in July's retail registrations

Amir Vijay Mohile
Mumbai

Honda Motorcycle & Scooter India (HMSI) emerged as India's top two-wheeler manufacturer by retail registrations in July, overtaking Hero MotoCorp for the first time in calendar year 2026. Honda's retail registrations rose 23 per cent year-on-year to 4,49,473 units, ahead of Hero MotoCorp's 4,19,456 units, which grew 20.6 per cent, according to Vahan data.

Overall two-wheeler registrations increased 22.3 per cent year-on-year to 17,34,624 units from 14,18,774 a year earlier. On a month-on-month basis, however, retail volumes declined 5.8 per cent from June's 18,41,713 units as monsoon seasonality weighed on demand.

Honda's July performance snapped Hero MotoCorp's six-month run at the top of the monthly Vahan retail rankings. Hero had led the market from January through June, driven by steady demand for its commuter motorcycle portfolio.

MARKET LEADERS

TVS Motor retained third place with 3,57,819 registrations, up 27.4 per cent year-on-year — the fastest growth among the top three manufacturers. Bajaj Auto followed with 1,71,790 registra-



VOOMING AHEAD. HMSI overtook Hero MotoCorp in July as industry registrations rose 22.3% year-on-year despite a seasonal moderation from June

tions, up 17.1 per cent, while Suzuki Motor India recorded 97,732 units, a 4 per cent increase.

Royal Enfield continued its strong momentum, posting 90,501 registrations, up 25.3 per cent, while the newly recorded 64,873 units, an increase of 23.6 per cent year-on-year.

INDUSTRY OUTLOOK

Hemal Thakkar, Senior Director and Senior Practice Leader at Crisil Intelligence, said the two-wheeler industry is expected to clock retail sales of over 1.8 million units in July, reflecting 26-27 per cent year-on-year growth. The month-on-month decline, he said, was in line with seasonal trends, while underlying demand remained healthy.

"ICE two-wheeler retail sales are expected to reach

1.6-1.65 million units, growing more than 22 per cent year-on-year. However, volumes are likely to decline by around 3 per cent from June, reflecting the seasonal moderation seen across the industry. Even so, ICE vehicles will continue to account for the bulk of industry volumes," Thakkar said.

Industry participants expect demand to remain resilient in the coming months, supported by rural recovery, replacement demand and the approaching festive season. Although registrations moderated sequentially in July, sustained double-digit annual growth suggests the domestic two-wheeler market remains on a firm footing, with conventional motorcycles and scooters continuing to dominate retail sales.

Maruti Suzuki banks on new plants, CNG push to sustain growth

Aishwarya Kumar
Bengaluru

Maruti Suzuki is banking on expanded manufacturing capacity, robust demand for CNG vehicles and a recovery in the entry-level car segment to sustain growth after posting its highest-ever monthly sales in July.

The country's largest car-maker crossed the 2-lakh monthly sales milestone for the first time, selling 2,00,123 units in July. According to Partho Banerjee, Senior Executive Officer — Marketing & Sales, only two other automotive brands globally have achieved this feat in their home markets. "We are not competing with anyone; we are competing with ourselves and trying to improve our benchmark month after month," Banerjee said, noting that the company achieved the record despite production disruptions in June.

CNG, SUVs

Maruti expects its recently commissioned plants at Hansapur and Kharkhoda to ease supply constraints over the next three to four months, helping it cater to festive season demand. Banerjee said the new facilities will ramp up production of SUVs and electric vehicles

while providing flexibility to manufacture multiple models based on market demand.

July sales were driven by broad-based demand across segments. Sales of small cars jumped 63 per cent, while SUV volumes grew 48 per cent year-on-year. The company also recorded its highest-ever monthly CNG sales of nearly 83,000 units, underscoring rising consumer preference for fuel-efficient vehicles amid elevated fuel prices.

Banerjee said the recently launched Brezza has received a strong response, attracting around 2,000 bookings a day across its three powertrain options. Maruti currently has a pending order book of lakh units, with production teams working to shorten waiting periods.

OUTLOOK POSITIVE

Banerjee said GST changes, lower repo rates and income tax relief for entry-level buyers continue to support demand. He added that the company's expanded CNG portfolio has helped offset the impact of higher fuel prices, with CNG sales growing around 50 per cent. He estimated the passenger vehicle industry expanded to 4.65-4.7 lakh units in July from about 3.5 lakh units a year earlier.

Adani Green to focus on ops, derisks biz with Adani Energy handling marketing

Avinash Nair
Ahmedabad

Adani Green Energy (AGEL) is de-risking its business by moving away from merchant renewable power sales and looking about 4-GW of generation into long-term supply agreements with group company Adani Energy Solutions (AESL).

"Our strategy is to de-risk ourselves. We concentrate more on operational excellence, project execution and deploying capital efficiently rather than taking market risk," Ashish Khanna, Chief Executive Officer of Adani Green, said recently.

The company indicated that the approach would also extend to future renewable and battery storage projects. "We are procuring power for merchant or commercial and industrial (C&I) sales. AESL, too, during its recent earnings call, said it has tied up around 5 GW of renewable supply capacity, of which about 4 GW has been contracted from AGEL and the balance from third-party renewable generators.

The company will increasingly earn predictable returns through long-term supply contracts, with AESL assuming the responsibility of marketing power to end-users.

Executives said the agreement was structured on an arm's-length, market-

linked basis and broadly mirrors conventional long-term renewable PPAs.

Solar and wind contracts are typically for 25 years, while battery energy storage system agreements run for 15 years, providing long-term revenue visibility. Khanna said the strategy would continue beyond the initial 4-GW portfolio.

MERCHANT MARKETS

The company will continue to monetise electricity in merchant markets only for projects commissioned before their contracted PPAs become operational. For AESL, the arrangement forms the foundation of its rapidly expanding energy solutions platform, under which it aggregates renewable generation, battery storage and power procurement to supply customised energy solutions to utilities, industries and data centres.

"Our objective would be that most of the tied-up capacity on the purchase side has also tied up on our sales side," said AESL Chief Executive Officer Kandarp Patel, adding that the company intends to convert most of its business into annuity-like revenues by matching long-term purchase agreements with long-term customer contracts. The company currently has around 350 MW of contracted C&I customers but said negotiations are at an advanced stage to secure long-term offtake agreements covering most of the renewable capacity already tied up. It expects demand to come increasingly from utilities, data centres and industrial consumers seeking round-the-clock renewable power backed by storage.

AESL said the energy solutions business has already transitioned into a full-scale vertical.

TATA POWER
(Corporate Contract Document)
The Tata Power Company Limited, Smart Center of Procurement Excellence, 3rd Floor, Sahar Receiving Station, New Hoort Lane, Sahar Airport Road, Aerodrome, Mumbai 400 015, Maharashtra, India
(Board Line: 022-4177177) (CIS: L2520W1919) (CIS000006)

NOTICE INVITING TENDER (NIT)
The Tata Power Company Limited invites tender from eligible vendors for the following tender package (Two-part Bidding) in Mumbai:
(A) Balance of Plant (BOP) services required for 110kV CK-3 line at Chikla & Kalyan and 110kV Transfer bus & bay at Dandi RSS. (Package Ref: C027N0K14).
Interested and eligible bidders to submit Tender/ Fee and Authorization Letter before 1500 hrs. Tuesday, 11th August 2026.
For detailed NIT, please visit Tender section on website <https://www.tatapower.com>. Also, all future correspondence is to be to the said tender will be published on Tender section of our website [Tata Power](https://www.tatapower.com) — Business Associates — Tender Documents only.

Alibaba unveils its largest AI model yet, DeepSeek's latest model is ultra cheap

Reuters
Beijing

China's Alibaba on Monday unveiled its largest and most capable AI model to date, sending its shares surging, while a research firm said DeepSeek's latest product offers cut-throat pricing that is more than 100 times cheaper than Anthropic's Claude Fable-5.

The two developments highlight the rapid pace of advancement in artificial intelligence by Chinese tech firms, which are locked in a fierce and fast-moving battle to build more powerful systems without making them prohibitively expensive to

run. Both models — Alibaba's Qwen3.8-Max and DeepSeek's V4-Flash — underlie Chinese commitment to open-weight models as the firms seek to gain traction among developers globally.

MANY PARAMETERS

"Chinese AI companies have found an important market. Many business workflows do not need the industry's very best model," said Lian Jye Su, Chief Analyst at research firm Omnia.

"They need models that are good enough, affordable, transparent and accessible, and open-weight models help meet that demand." Alibaba's new Qwen3.8-

Max immediately shot up leaderboards assessing the capabilities of AI models after being unveiled on Monday, helping its shares jump seven per cent in Hong Kong trade.

The model has 2.4 trillion parameters, the numerical settings a model learns from data and uses to recognise patterns, generate answers, and carry out tasks.

POPULAR MODELS

Qwen3.8-Max was unveiled on crowdsourced, model-comparison platform Arena.AI.

It soon became the highest ranking Chinese model in terms of text models, though it still lags Claude

Fable-5 and three OpenAI variants which are all from Anthropic.

DeepSeek's V4-Flash model, released on Friday, is by far the least expensive to run on benchmark tests among well-known models globally, according to research firm Artificial Analysis. V4-Flash charges \$0.14 per million input tokens and \$0.28 per million output tokens, according to San Francisco-based Artificial Analysis.

Artificial Analysis estimated V4-Flash's average cost at 3 cents per test, compared with 86 cents for Kimi K3, \$1.86 for OpenAI's GPT-5.5 Sol and \$3.15 for Claude Fable-5.

SAMBHV STEEL TUBES LIMITED
CIN No. 272302GT2017PLC007918
Registered Office: Office No. 501 to 511 Harshiti Corporate, Amanaka, Rajpur (C.G) India, 492001, Tel: 0771-2222360, Email: cs@sambhv.com, Website: www.sambhv.com

Statement of Unaudited Consolidated & Standalone Financial Results for the Quarter Ended June 30, 2026.

The Unaudited Standalone and Consolidated Financial Results of Sambhav Steel Tubes Limited ("the Company") along with the Limited Review Reports of the Statutory Auditors of the Company for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their Meetings held on August 03, 2026, in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The results along with the Limited Review Reports have been posted on the Company's website at <https://www.sambhv.com/financial-performance.php> and on stock exchanges website www.nseindia.com and www.bseindia.com. The results can also be accessed by scanning the QR Code.

For and on behalf of the Board of Directors of Sambhav Steel Tubes Limited
Sd/-
Vikas Kumar Goyal
Managing Director and CEO
DIN: 00318182

Place: Raipur
Date: August 03, 2026

Note: The above information is in accordance with Regulation 33 read with Regulation 47(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015.